RESUMO
In 80 normal puerperae, serum follicle-stimulating hormone (FSH), luteinizing hormone (LH), including human chorionic gonadotropin (hCG/LH), and prolactin (PRL) levels were evaluated 6 to 29 hours after vaginal delivery. In these puerperae, PRL levels were higher and FSH levels were lower than in menstruating women; hCG/LH levels were very high, due to persisting hCG levels. The values of the three hormones showed a log-normal distribution, and no relationship was found between the three hormones considered in pairs. Thirty-six puerperae chosen from the above 80 were followed during a 5-day period: 24 were not able to breast-feed their babies and were treated with metergoline, an antiserotoninergic agent able to prevent puerperal lactation, 8 or 12 mg/day; 12 additional puerperae, nursing their babies, were evaluated as controls. In lactating women PRL and FSH levels remained steady during the observation period, while hCG/LH levels progressively decreased. Metergoline lowered PRL levels, when employed at both dosages, and FSH levels only at the higher dosage, without affecting the decline of hCG/LH levels. Since dopaminergic drugs are known to lower serum LH levels and not to affect or to increase FSH levels, our data indicate that metergoline might act through a mechanism of action different from dopaminergic drugs.
Assuntos
Ergolinas/uso terapêutico , Hormônio Foliculoestimulante/sangue , Hormônio Luteinizante/sangue , Metergolina/uso terapêutico , Período Pós-Parto , Prolactina/sangue , Adolescente , Adulto , Gonadotropina Coriônica/sangue , Feminino , Humanos , Lactação/efeitos dos fármacos , Metergolina/administração & dosagem , Gravidez , Fatores de TempoRESUMO
Forty patients with hyperprolactinaemia were treated with metergoline (8 to 12 mg/day) for periods up to 5 years. Analysis of the results of clinical and biological tolerability showed that treatment was generally well tolerated and although 28 patients complained of drug-related side-effects of various kinds, principally nausea, these were usually mild, present at the beginning of treatment and disappeared spontaneously in spite of continued metergoline administration over a prolonged period. No patient stopped treatment because of side-effects. Laboratory parameters also stayed within normal levels and there was no evidence of any alterations in the ECG. It is concluded, therefore, that metergoline is a well-tolerated as well as an effective ergolinic compound for use in those patients in whom prolonged treatment with a prolactin-lowering drug is considered necessary.
Assuntos
Ergolinas/efeitos adversos , Metergolina/efeitos adversos , Prolactina/sangue , Adenoma/metabolismo , Adulto , Tolerância a Medicamentos , Feminino , Humanos , Neoplasias Hipofisárias/metabolismo , Prolactina/metabolismo , Fibrose Retroperitoneal/induzido quimicamente , Fatores de TempoRESUMO
8 or 12 mg/day methergolin was administered for an average of 8 months to 80 patients with hyperprolactinaemia of tumoural (20 cases), idiopathic (39 cases), and iatrogenic (21 cases) origin. The success of the treatment was apparent in the return of ovulation and the establishment of pregnancy in 80% of patients with microadenoma, and 85% of those with a normal sella turcica.
Assuntos
Adenoma/tratamento farmacológico , Ergolinas/uso terapêutico , Metergolina/uso terapêutico , Neoplasias Hipofisárias/tratamento farmacológico , Prolactina/sangue , Adolescente , Adulto , Relação Dose-Resposta a Droga , Feminino , Galactorreia/tratamento farmacológico , Humanos , Ovulação/efeitos dos fármacos , Gravidez , Sela Túrcica/patologiaRESUMO
84 patients with elevated serum PRL levels, ranging from 25 to 253 ng/ml, were treated with an antiserotonin agent, metergoline, at the dose of 12 mg/day for 90 days. The clinical complaint was of amenorrhea in 70 cases (plus galactorrhea in 44 cases) and of anovulation in 14 cases (plus galactorrhea in 6 cases). Hyperprolactinemia was due to a pituitary adenoma in 18 cases; in 53 cases it was of unknown origin, while in 7 cases it followed treatment with neuroleptics or with oral contraceptives and in 6 cases it followed a puerperium. In patients with amenorrhea, metergoline induced the appearance of menses in 61 cases (94%), and of ovulation in 46 cases (82%). In 13 of the 14 patients with anovulation, ovulation was restored. Galactorrhea disappeared in 40 out of 50 patients. Metergoline normalized serum PRL levels (less than 20 ng/ml) in 46 cases and significantly reduced serum PRL levels in all but 3 of the remaining patients. In spite of suggested nonhormonal contraceptive measures, 14 patients became pregnant; 2 had abortions and the remaining 12 patients completed by vaginal delivery, uneventful pregnancies. These results indicate metergoline as a safe and effective drug in the management of hyperprolactinemic amenorrhea and anovulation. 49 patients were followed for 2 additional months, receiving no treatment (24 cases) or metergoline at a reduced daily dosage (8 mg/day, 25 cases). Within 60 days, 60% of the first group had relapse of the clinical condition and a rebound elevation of serum PRL levels while only 20% of the second group experienced relapse of amenorrhea and rebound elevation of serum PRL levels (p less than 0.01).